Lifestyle coaching is feasible in fatigued brain tumor patients: A phase I/feasibility, multi-center, mixed-methods randomized controlled trial

Alasdair G. Rooney, William Hewins, Amie Walker, Mairi Mackinnon, Lisa Withington, Sara Robson, Claire Torrens, Lisa E. M. Hopcroft, Antony Clark, Garry Anderson, Helen Bulbeck, Joanna Dunlop, Michelle Welsh, Aimee Dyson, Julie Emerson, Carol Cochrane, Robert Hill, Jade Carruthers, Julia Day, David Gillespie, Christopher Hewitt, Emanuela Molinari, Mary Wells, Catherine McBain, Anthony J. Chalmers, and Robin Grant

Abstract

Background. There are no effective treatments for brain tumor-related fatigue. We studied the feasibility of two novel lifestyle coaching interventions in fatigued brain tumor patients.

Methods. This phase I/feasibility multi-center RCT recruited patients with a clinically stable primary brain tumor and significant fatigue (mean Brief Fatigue Inventory [BFI] score ≥ 4/10). Participants were randomized in a 1–1–1 allocation ratio to: Control (usual care); Health Coaching (“HC”, an eight-week program targeting lifestyle behaviors); or HC plus Activation Coaching (“HC + AC”, further targeting self-efficacy). The primary outcome was feasibility of recruitment and retention. Secondary outcomes were intervention acceptability, which was evaluated via qualitative interview, and safety. Exploratory quantitative outcomes were measured at baseline (T0), post-interventions (T1, 10 weeks), and endpoint (T2, 16 weeks).

Results. n = 46 fatigued brain tumor patients (T0 BFI mean = 6.8/10) were recruited and 34 were retained to endpoint, establishing feasibility. Engagement with interventions was sustained over time. Qualitative interviews (n = 21) suggested that coaching interventions were broadly acceptable, although mediated by participant outlook and prior lifestyle. Coaching led to significant improvements in fatigue (improvement in BFI versus control at T1: HC=2.2 points [95% CI 0.6, 3.8], HC + AC = 1.8 [0.1, 3.4], Cohen's d [HC] = 1.9; improvement in FACIT-Fatigue: HC = 4.8 points [-3.7, 13.3]; HC + AC = 12 [3.5, 20.5], d [HC and AC] = 0.9). Coaching also improved depressive and mental health outcomes. Modeling suggested a potential limiting effect of higher baseline depressive symptoms.

Conclusions. Lifestyle coaching interventions are feasible to deliver to fatigued brain tumor patients. They were manageable, acceptable, and safe, with preliminary evidence of benefit on fatigue and mental health outcomes. Larger trials of efficacy are justified.

Keywords

brain tumor | coaching | fatigue | lifestyle | RCT
Brain tumor-related fatigue is a common and pervasive problem. Frequency estimates for fatigue range from 39 to 96\%\(^1,2\) seemingly irrespective of brain tumor grade,\(^3\) histology,\(^4\) or clinical time-point,\(^5\) and often comorbid with cognitive impairment or depressive symptoms.\(^6,7\) The profound impact of fatigue\(^8,7\) is widely recognized. For example, The Brain Tumour Charity highlights its devastating impact on a person's capacity to cope with daily life,\(^8\) while the UK James Lind Alliance considers the management of fatigue to be a top research priority for the neuro-oncology community.\(^9\)

There is a lack of evidence to underpin effective management of brain tumor-related fatigue,\(^10\) despite several psychostimulant drug trials over the past decade. Trials of Methylphenidate and Armodafinil included non-fatigued patients,\(^11\)–\(^13\) while studies of Modafinil, Dexamphetamine, and Methylphenidate recruited only highly fatigued patients but found no evidence of benefit over placebo on their primary outcome of fatigue.\(^14\)–\(^16\)

Non-pharmacological treatments are a proposed alternative to medication for many cancer-related symptoms.\(^17\)–\(^19\) Some of these treatments incorporate more complex “lifestyle coaching” approaches that aim to reinforce healthy behavior,\(^20\) social activity,\(^21\) stress reduction,\(^22\) exercise,\(^23\) and/or better dietary habits.\(^24\) Lifestyle coaching interventions have shown promise in alleviating fatigue in patients with cancers arising out-with the CNS.\(^25\) Within neuro-oncology it was established recently that exercise\(^23\) and yoga\(^26\) are feasible to deliver to non-fatigued patients. However, lifestyle coaching interventions have not been studied in highly fatigued patients. These patients are often quite impaired, and it is far from clear whether they would find such interventions feasible and acceptable.

We therefore developed BT-LIFE (Brain Tumors, Lifestyle Interventions, and Fatigue Evaluation), a pilot (Phase I feasibility) randomized controlled trial of two lifestyle coaching interventions for clinically significant brain tumor-related fatigue. The first intervention, “Health Coaching”; promoted a healthy lifestyle. The second, “Activation Coaching”; promoted self-efficacy. Both interventions are described in detail below. Our primary aim was to determine the feasibility of recruiting and retaining brain tumor patients with moderate or severe fatigue to HC and AC interventions. Secondary aims were to determine interventional acceptability, engagement, and safety; and to gather exploratory outcome data to inform a larger trial.

**Methods**

**Trial Design**

BT-LIFE was a Phase I feasibility, multi-center, mixed-methods, three-arm randomized controlled trial with 1:1:1 allocation stratifying by center (ISRCTN17883425, Supplementary Figure S1). The study was coordinated by the Scottish Clinical Trials Research Unit. The final study protocol is presented in Supplementary Methods.

**Participants**

Eligible participants were: aged 18+; diagnosed with a primary brain tumor of any grade or histological subtype; ≥ 3 months after completion of primary treatment (any combination of surgery, radiotherapy and/or chemotherapy) with no evidence of disease progression; and clinically significantly fatigued (mean Brief Fatigue Inventory [BFI] score of at least 4/10).\(^27\) Exclusion criteria were: low fatigue (mean BFI < 4/10); clinical concern about disease progression; clinically adjudged severe cognitive, language, or visual impairment; or inability to give informed consent.

Participants were recruited from neuro-oncology outpatient clinics in three UK centers (Edinburgh, Glasgow, and Manchester). Patients describing fatigue in their usual clinical appointment and who showed interest in the trial were screened for eligibility. WHO tumor grade was based on WHO 2016 diagnostic criteria. Baseline and follow-up trial outcome data were gathered face-to-face. These outcome assessments usually occurred in clinical settings with reimbursement of travel costs. Rarely (< 5\% of cases) other locations were used such as the participant’s home.

**Interventions**

**Control.**—Control arm participants received the Brain Tumour Charity’s information leaflet about fatigue and “Usual Care.” The information leaflet included written advice on managing fatigue. In our centers Usual Care included ongoing access to the neuro-oncology clinical team with routine scheduled follow-up appointments.

**Health Coaching (HC).**—Participants in this arm received the information leaflet plus Health Coaching (hereafter HC). HC was a multimodal lifestyle coaching intervention which promoted incremental patient-led improvements in: fluid intake (reducing caffeine and alcohol and drinking more water); sleep (promoting rest); diet (encouraging healthy eating); exercise and movement (increasing number of steps per day); and reducing stress. Our HC model was developed in private practice by an accredited personal trainer. This individual (GA) delivered HC to patients recruited in Edinburgh and Glasgow. In Manchester HC was delivered by an NHS physiotherapist (AD) working to the same format.

Participants were offered eight weekly HC sessions. In this pilot study none of the sessions were formally manualized. However, efforts were made to standardize them between sites and patients. The initial session was a standardized 45-min face-to-face assessment with the Health Coach (Supplementary Methods). Each participant was provided with an infographic reminder card (Supplementary Figure S2), a wearable step counter (Omnicon), and a daily home diary (Supplementary Figure S3). Up to seven 30-min follow-up sessions were then delivered weekly by telephone or in person, informed by the diary and tailored to individual goals. These follow-up sessions followed a set structure (Supplementary Methods) with their content reflecting the goals and progress of individual patients.

**Health Coaching plus Activation Coaching (HC + AC).**—Participants in this arm received the above, plus Activation Coaching (AC). AC was developed by the UK brain tumor charity braintrust. AC was targeted at coaching
improvement in participants’ self-efficacy for managing fatigue. It was delivered by trained life coaches in two 1-hour sessions for each patient, with sessions separated by 4 weeks. Before each AC session participants completed the Patient Activation Measure (PAM) to inform the coach about the individual’s current level of knowledge, skills, and confidence about fatigue. AC then focused on promoting self-efficacy using Dilts’ Logical Levels in session one, and the FRAME and GROW models in sessions one and two (Supplementary Methods). During the trial this arm had been called simply “Patient Activation.” We have since re-named the intervention “Activation Coaching” to distinguish it more clearly from the original Patient Activation Measure to which it is unrelated.

Primary Outcome

The primary outcome was feasibility of recruitment and retention. Recruitment feasibility required a recruitment rate “equivalent to 60 fatigued patients over 12 months.” This rate would permit a larger trial to recruit in a timely manner. Retention feasibility required all-cause attrition of under 40% at the study endpoint. There is no agreed critical threshold for attrition in QOL outcomes from cancer RCTs. In neuro-oncology attrition is often high: leading studies of QOL outcomes in highly impaired patients may report missing data frequency (even among surviving patients) of over 30% on outcome measures at four months. In such an understudied group we also anticipated a process of learning and systems development to iteratively minimize both avoidable attrition, and the impact of unavoidable attrition, which might inform future trials of interventions for brain tumor-related fatigue.

Secondary and Exploratory Outcomes

Secondary outcomes were the acceptability of, and engagement with, the interventions among participants (evaluated by sessional attendance, diary inspection, and qualitative interviews). A further secondary outcome was to explore potential benefit via a quantitative analysis of qualitative interviews. A further secondary outcome was to explore potential benefit via a quantitative analysis of qualitative interviews. A further secondary outcome was to explore potential benefit via a quantitative analysis of qualitative interviews.

Qualitative Interviews

All those completing HC (+/- AC) were invited to participate in a semi-structured qualitative interview about their experiences and the perceived acceptability of the interventions. Interviews were guided by a template (Supplementary Methods), conducted by a qualitative researcher or allied health professional blinded to treatment allocation, audio-recorded, and transcribed. Interviews were audio-recorded, transcripts were analyzed using the framework method: (1) Familiarization; (2) Construction of initial themes; (3) Indexing and sorting; (4) Review; and (5) Data summary. A realist approach provided a thematic framework (Context-Mechanism-Outcome) to analyze transcripts.

Sample Size Calculation

Sample sizes were not calculated for this feasibility study. Results were used instead to calculate sample sizes for a future Phase II trial of efficacy (see Supplementary Methods).

Randomization and Follow-Up

After obtaining informed consent a Research Assistant administered baseline measures. They accessed www.sealedenvelope.com to randomize with stratification by study site. It was not possible to blind participants or Research Assistants to allocation. Follow-up assessments were conducted 10 weeks (T1) and 16 weeks (T2) after randomization. The T1 time-point was chosen to measure symptoms shortly after the end of the 8-week intervention—assumed to represent the point of maximal signal, if any. The T2 time-point was chosen to allow a modest period of follow-up extending to a total of four months after baseline, to examine for early attenuation of any signal in this pilot study.

Statistical Analyses: Primary Outcomes

For recruitment feasibility, the number of patients recruited was compared to the target rate of 60 patients per year. The number and proportion of patients retained to the T2 endpoint was compared to the target that at least 60% of patients should be retained.

Statistical Analyses: Exploratory Outcomes

Box-and-whisker plots were produced for each outcome score, broken down by treatment arm and separated by time-point. Changes to outcome scale scores from T0 (baseline) to T2 (endpoint) were compared among the study arms using a one-way ANOVA. Ninety-five percent confidence intervals were produced and two sided post-hoc comparisons made using Bonferroni (equal variances assumed) and Dunnett’s C (equal variances not assumed) statistics. A significance level of .05 was used. Waterfall plots were constructed to examine whether intervention arm effects clustered separately from control arm effects. Further statistical analysis detail is given in Supplementary Methods and below.

Data Protection and Ethics

All participants gave written informed consent and GDPR-specific consent. The trial team used encrypted nhs.net email for all written communication. The trial was ethically approved by the South-East Scotland Research Ethics Committee 2 (18/SS/0025) and the local Caldicott Guardian.
Results

Primary Outcome: It was Feasible to Recruit and Retain Fatigued Brain Tumor Patients

During a 9-month recruitment period (16th August 2018–15th May 2019) \( n = 103 \) primary brain tumor patients were screened from whom \( n = 46 \) fatigued patients were recruited (Figure 1, Table 1 and Supplementary Figure S4). This recruitment rate equated to 61 participants in 12 months, establishing recruitment feasibility (Figure 2A). At T2 endpoint 34/46 participants remained (retention = 74% [95% CI = 59, 86%], Figure 2B) establishing retention feasibility. Recruitment and retention were generally acceptable across sites and arms (Supplementary Table S1). The most frequent reason for drop-out was withdrawal of consent due for example to interventional burden, difficulty traveling, family commitments, and medical illness (for full details see Figure 1).

In this small study the intervention arms were balanced on most characteristics, but participants randomized to HC were significantly younger. At baseline the groups also differed on the PSYCHLOPS outcome measure: participants in the HC arm reported better function and participants in the HC+AC arm reported poorer function on this scale, relative to controls (Table 1).

Secondary Outcome: Lifestyle Coaching was Acceptable, Manageable, and Safe

Acceptability and engagement.—Fifteen participants received Control and 31 patients were randomized to an intervention (Figure 1, HC \( n = 16 \), HC + AC \( n = 15 \)). Two participants randomized to HC + AC dropped out for unrelated medical reasons before starting any intervention. Those remaining started HC on average 17 days (SD = 9, range = 2–36) after randomization, completing a median of seven sessions (IQR = 6–8, mode = 8, range = 1–8, Figure 2C). The first AC session occurred after a median of four HC sessions and the second after seven. All patients who received the first AC session also completed the second.

Participants returned a median of seven diaries (maximum = 8). Those remaining in the study throughout showed high rates of diary return (median = 7 diaries returned, mode = 8, range = 3–8), unlike those destined to drop-out (median = 0 diaries, mode = 0, range = 0–8) (Figure 2C). Each diary contained 106 individual cells to optionally complete. Among participants returning at least one diary (\( n = 25/31 \)) mean cell completion was 67.2% (SD = 14.2%,
Table 1. Baseline demographic characteristics

|                      | Control (n = 15) | Health coaching (n = 16) | Health + Activation coaching (n = 15) | Total (n = 46) | \( P \) |
|----------------------|------------------|-------------------------|--------------------------------------|----------------|--------|
| Age (mean, SD)       | 46 (10)          | 38 (10)                 | 49 (13)                              | 44 (12)        | .031^   |
| Sex (M/F)            | 5/10             | 9/7                     | 6/9                                  | 20/26          | .414^b  |
| WHO tumor grade (n)  |                  |                         |                                      |                | .951^c  |
| I                    | 2                | 4                       | 4                                    | 10             |        |
| II                   | 6                | 5                       | 4                                    | 15             |        |
| III                  | 4                | 5                       | 5                                    | 14             |        |
| IV                   | 2                | 2                       | 1                                    | 5              |        |
| Not known            | 1                | 0                       | 1                                    | 2              |        |
| Tumor location*      |                  |                         |                                      |                | .993^b  |
| Frontal lobe involvement | 6              | 6                       | 5                                    | 17             |        |
| Temporal lobe involvement | 4              | 4                       | 4                                    | 12             |        |
| Other location       | 6                | 8                       | 8                                    | 22             |        |
| Tumor laterality     |                  |                         |                                      |                | .728^b  |
| Left                 | 5                | 5                       | 7                                    | 17             |        |
| Right                | 8                | 9                       | 7                                    | 24             |        |
| Both                 | 1                | 1                       | 1                                    | 3              |        |
| Midline              | 1                | 1                       | 0                                    | 2              |        |
| Surgery**            |                  |                         |                                      |                | .638^b  |
| Yes                  | 15               | 14                      | 14                                   | 43             |        |
| No                   | 0                | 2                       | 1                                    | 3              |        |
| Type of surgery (n = 43) |              |                         |                                      |                | .815^b  |
| Biopsy               | 3                | 3                       | 4                                    | 10             |        |
| Resection            | 12               | 11                      | 9                                    | 32             |        |
| Data missing         | 0                | 0                       | 1                                    | 1              |        |
| Chemotherapy**       |                  |                         |                                      |                | .868^b  |
| Yes                  | 8                | 10                      | 9                                    | 27             |        |
| No                   | 7                | 6                       | 6                                    | 19             |        |
| Radiotherapy**       |                  |                         |                                      |                | .313^b  |
| Yes                  | 11               | 14                      | 14                                   | 39             |        |
| No                   | 4                | 2                       | 1                                    | 7              |        |
| KPS                  |                  |                         |                                      |                | .599^b  |
| 90–100               | 5                | 8                       | 7                                    | 20             |        |
| 70–80                | 9                | 8                       | 6                                    | 23             |        |
| < 70                 | 1                | 0                       | 1                                    | 2              |        |
| Data missing         | 0                | 0                       | 1                                    | 1              |        |
| Medications at baseline (n)* |              |                         |                                      |                | NA^e   |
| EIAED                | 3                | 2                       | 0                                    | 5              |        |
| Non-EIAED            | 8                | 8                       | 9                                    | 25             |        |
| Antidepressant       | 8                | 8                       | 5                                    | 21             |        |
| Non-opiate analgesia | 3                | 2                       | 1                                    | 6              |        |
| Opiate analgesia     | 4                | 1                       | 2                                    | 7              |        |
| Vitamin supplementation | 4              | 2                       | 1                                    | 7              |        |
| Hormonal replacements | 3              | 4                       | 3                                    | 10             |        |
| Measures (mean, SD)  |                  |                         |                                      |                |        |
| BFI                  | 7.0 (1.5)        | 6.4 (1.4)               | 7.1 (1.3)                            | 6.8 (1.4)      | .307^a  |
| FACIT-Fatigue        | 21.3 (8.5)       | 24.9 (10.0)             | 19.5 (7.5)                           | 22.0 (8.8)     | .233^a  |

\(^{a}\) \text{Bonferroni correction applied.}
\(^{b}\) \text{Chi-square test.}
\(^{c}\) \text{ANOVA (Tukey posthoc test).}
\(^{d}\) \text{Chi-square test with Yates’s correction.}
\(^{e}\) \text{Data not available (NA).}
range = 35–90%). Cell completion was similar between intervention groups and remained stable throughout the study (Figure 2D1) with no evidence of “diary fatigue” over time.

We examined step count data as an objective test of engagement with HC. In 23/31 participants returning step data, the mean weekly count was 6674 steps (SD = 2815, range = 2569–12 099), with no significant difference in frequency between intervention arms. In an exploratory post-hoc analysis there was a positive effect of coaching over time (mean steps in the first half of coaching = 6273/week [SD = 2834]; second half of coaching = 7031/week [SD = 2798], paired-samples t-test P = .027). Normalized to their performance in the first half of coaching, participants showed a 17% increase in physical activity in the second half (SD = 29%, range −21 to +83%, Figure 2D). These modest improvements suggested that coaching could improve outcomes in fatigued patients.

Participants completed outcome questionnaires well. At T0 baseline (n = 46) questionnaire completion was 100% except for the FACIT-F (45/46 completed). At T1 (n = 36) questionnaire completion was 35/36 for all questionnaires, due to one participant missing the T1 appointment, except PSYCHLOPS (33/36) and ACE-III (34/36). At T2 (n = 34), questionnaire completion was 100% except for PSYCHLOPS (30/34), EQ-5D (33/34) and HADS (33/34). The completion of all potential questionnaires at all potential timepoints was 97.7% (907 actual versus 928 potential data points).

**Qualitative feedback.**—Among patients who completed HC or HC + AC, n = 21 were interviewed in detail about their experience of the interventions. This sub-sample included 10 female and 11 male participants aged between 25 and 63 (mean age 44). Participants came from both the HC (n = 9) and HC + AC (n = 12) arms of the trial, and from all three sites: NHS GGC (n = 10), NHS Lothian (n = 8) and The Christie Hospital, Manchester (n = 3). They represented a spectrum of fatigue with moderate (n = 13) and severe (n = 8) levels of baseline BFI fatigue.

Overall acceptability was good although influenced by contextual factors, including patient expectations and attitudes to life, prior experience of making lifestyle changes, and the emotional and physical constraints of living with a brain tumor. The degree to which the coaching approach was perceived to “fit” with the individual’s beliefs and way of life was important to overall engagement with the interventions.

Some patients found the interventions compatible with their needs whereas others expressed needs that were unmet by the coaching approach. Potential mechanisms of change included pragmatic factors such as goal-setting and monitoring, and supportive factors such as the motivational “push” from coaches and family or friends. Many participants also reported improved general wellbeing and awareness of health behaviors. Some individuals reported specific improvements in fatigue including being “better able to cope” with fatigue. Full qualitative results will be reported elsewhere.

**Adverse events.**—No adverse events were reported and no patients were withdrawn from the trial by study investigators.

**Exploratory Outcomes: Coaching Improved Fatigue and Mental Health**

**Fatigue.**—At T1, both intervention arms showed statistically significant improvements in BFI scores relative to change in the control arm (T1–T0 BFI improvement over control: HC = 2.2 point improvement [95% CI 0.6, 3.8 points, Cohen’s d = 1.88], HC + AC = 1.8 [0.1, 3.4, d = 1.10], one-way ANOVA P = .004). FACIT-Fatigue scores also improved in both arms with clinical and statistical significance in the HC + AC arm (T1–T0 FACIT-Fatigue improvement over control: HC = 4.8 points [−3.7, 13.3, d = 0.47]; HC + AC = 12 [3.5, 20.5, d = 0.89]; one-way ANOVA P = .01) (Figure 3A1,2 and Table 2). In the HC + AC arm, FACIT-Fatigue improvement

---

**Table 1. Continued**

|                | Control (n = 15) | Health coaching (n = 16) | Health + Activation coaching (n = 15) | Total (n = 46) | P |
|----------------|-----------------|-------------------------|--------------------------------------|---------------|---|
| HADS-D         | 8.7 (3.6)       | 6.9 (3.7)               | 8.1 (3.4)                            | 7.8 (3.6)     | .369*|
| HADS-A         | 11.3 (5.2)      | 7.9 (4.5)               | 10.0 (4.6)                           | 9.7 (4.8)     | .143*|
| PSYCHLOPS      | 14.7 (3.1)      | 12.6 (3.6)              | 16.1 (3.3)                           | 14.4 (3.6)    | .017*|
| EQ-5D health   | 12.3 (4.1)      | 10.1 (3.1)              | 10.9 (2.9)                           | 11.1 (3.4)    | .201*|
| EQ-5D VAS      | 53.1 (18.6)     | 55.4 (24.5)             | 50.2 (20.0)                          | 53.0 (20.9)   | .796*|
| ACE-III        | 86.7 (9.4)      | 89.8 (75)               | 89.1 (78)                            | 88.6 (8.2)    | .559*|

All analytic tests on baseline demographic data were post-hoc. Significant P values are shown in bold.

*Totals may sum > 46 due to potential for one patient to fill multiple categories.

**For duration since surgery, chemotherapy, or radiotherapy in individual participants see Supplementary Figure S4.**

**One-way ANOVA.**

**Chi Square.**

**Cells containing “1” or “0” excluded from statistical analysis.**

---

---
was sustained to endpoint (T2–T0 improvement on control: 
HC = 3.2 points [−5.4, 11.8, d = 0.49]; HC + AC = 9.9 [1.3, 18.5, 
d = 1.15]; one-way ANOVA P = .03). Two-way mixed ANOVA 
found significant interactions between arm and time for 
both fatigue scales (Supplementary Results). Waterfall 
plots of T1–T0 improvement suggested that both inter-
ventions had acute benefits on fatigue versus control with no 
consistent separation of the two active intervention groups 
(Figure 3B1,2 and Table 2).

Mental health.—Depressive symptoms (HADS-D scores) 
improved at T1 in the HC + AC arm (Kruskal–Wallis P = .02, 
Dunnett’s post-hoc P = .01, Cohen’s d = 0.92) (Figure 3A3, 
B3 and Table 2). PSYCHLOPS scores improved in the com-
bined HC + AC arm at T1 (Fig 3A4, B4 and Table 2, ANOVA 
P = .01, post-hoc Bonferroni P = .01, Cohen’s d = 1.5), sus-
tained at T2 (ANOVA P = .02, Bonferroni P = .02, Cohen’s 
d = 1.7). No significant changes in HADS anxiety, EQ-5D 
Health Status, or ACE-III cognition were found (Table 2 and 
Supplementary Figure S5).

Severe depressive symptoms may limit potential coaching 
benefits.—Correlation of baseline measures with BFI im-
provement at T1 were negative (Figure 3C1), suggesting

Figure 2. Lifestyle coaching was feasible to deliver and acceptable to fatigued patients. (A) Graph of cumulative recruitment between 16th Aug 2018 and 16th May 2019. The straight line is the target rate of 60 fatigued patients per year. (B) Individual patient attendance at T0, T1, and T2 outcome assessments. (C) Individual patient attendance at scheduled coaching sessions. Patient drop-out is marked in dark grey. (D1) % Diary completion (out of 106 possible fields per week). Each grey line is the course of one patient over 8 weeks of Health Coaching. The linear regres-
sion slope is shown by the thicker black line and demonstrates no reduction in diary completion over time. (D2) Steps per week measured by ob-
jective step counters. As shown by the thicker black regression line, step number increased slightly in the second half of HC compared to the first 
(paired-samples t-test P = .027). Individual level data for (D1) and (D2) are available from the corresponding author on request.
that coaching had greater impact in participants who were relatively less impaired at baseline. As there were no clear differences of effect between the two intervention arms, we combined them to create one “grouped interventions” arm in exploratory modeling analyses. Linear modeling showed a mean T1 BFI improvement of 2.5 points (95% CI 1.8, 3.2) in the “grouped interventions” arm compared to the control arm (Supplementary Table S5). This model explained 28.6% of BFI score variation at T1 (adjusted $R^2 = 26.3$%).

To explore whether depressive symptoms mediated this improvement, a second linear model considered baseline HADS-depression (HADS-D$_{T0}$) scores in addition to allocation. In the “grouped interventions” arm, baseline HADS-depression was a significant explanatory variable for the change in BFI at T1 (Supplementary Table S5, Figure 3C). As baseline HADS-depression increased there was less improvement on the BFI following an intervention. This improved model explained 42.5% (adjusted $R^2 = 36.8$%) of the variance, suggesting that patients with lower depression scores at baseline may benefit more from lifestyle coaching for fatigue.

**Discussion**

It is feasible to deliver lifestyle coaching interventions to fatigued brain tumor patients. Willingness to take part and
remain in BT-LIFE was high and most participants engaged meaningfully with the coaching procedures. Qualitative analysis suggested that the compatibility of coaching with an individual’s prior experiences was a key mediator of engagement. There were favorable but preliminary signals of beneficial effects on fatigue, psychological outcomes, and depressive symptoms. Exploratory modeling suggested a limiting effect of higher depressive symptoms on the effect of coaching on fatigue. Our data suggest that patients who were moderately rather than extremely impaired, and who “believe” in a coaching approach, may be more likely to benefit—but much more study is needed.

| Scale (range) | T0 baseline | T1 (vs T0) | T2 (vs T0) |
|--------------|-------------|------------|------------|
|              | Mean score (SD) | Mean change (SD) | One-way ANOVA P | Mean change (SD) | One-way ANOVA P |
| BFI (0–10)   |             |            |            |
| Control      | 6.6 (1.6)   | −0.59 (1.3) | .004       | −1.2 (1.5)     | .374           |
| Health Coaching | 6.2 (1.4)  | −2.71 (1.4) |            | −2.1 (2.6)     |               |
| Health + Activation Coaching | 6.7 (1.1) | −2.26 (2.1) |            | −2.5 (2.1)     |               |
| FACIT-Fatigue (0–52) |         |            |            |
| Control      | 21.5 (8.2)  | −1.0 (4.5)  | .009       | +1.3 (5.1)     | .025           |
| Health Coaching | 24.9 (10.3)| +3.8 (8.1)  |            | +4.5 (9.1)     |               |
| Health + Activation Coaching | 19.5 (75) | +11.0 (12.3)|            | +11.2 (9.7)    |               |
| HADS-D (0–21) |             |            |            |
| Control      | 8.7 (3.6)   | +0.85 (3.1) | .009       | −1.2 (2.8)     | .327           |
| Health Coaching | 6.9 (3.7)  | −2.00 (2.4) |            | −0.8 (2.7)     |               |
| Health + Activation Coaching | 8.1 (3.4) | −2.91 (3.1) |            | −2.6 (3.4)     |               |
| HADS-A (0–21) |             |            |            |
| Control      | 11.3 (5.2)  | −1.1 (2.1)  | .235       | −1.6 (3.4)     | .333           |
| Health Coaching | 7.9 (4.5)  | −0.0 (3.4)  |            | +0.1 (4.5)     |               |
| Health + Activation Coaching | 10.0 (4.6)| −2.1 (3.0)  |            | −2.4 (3.6)     |               |
| PSYCHLOPS (0–20) |          |            |            |
| Control      | 15 (3.1)    | −0.67 (3.5) | .007       | −1.1 (3.5)     | .018           |
| Health Coaching | 13 (3.6)   | −3.09 (3.5) |            | −2.4 (4.1)     |               |
| Health + Activation Coaching | 16 (3.3) | −6.00 (4.0) |            | −6.1 (3.7)     |               |
| EQ-5D Health (5–25) |          |            |            |
| Control      | 12 (4.1)    | −0.54 (2.7) | .327       | −2.18 (3.1)    | .451           |
| Health Coaching | 10 (3.1)   | −2.09 (2.3) |            | −1.82 (2.8)    |               |
| Health + Activation Coaching | 11 (2.9) | −0.91 (2.6) |            | −0.73 (2.4)    |               |
| EQ-5D VAS (0–100) |        |            |            |
| Control      | 53 (19)     | +5.2 (25)   | .202       | +3.9 (20)      | .374           |
| Health Coaching | 55 (25)    | +6.5 (20)   |            | +6.2 (20)      |               |
| Health + Activation Coaching | 50 (20) | +21.2 (23)  |            | +17.6 (31)     |               |
| ACE-III (0–100) |           |            |            |
| Control      | 87 (9.4)    | +3.00 (7.6) | .616       | +3.1 (7.6)     | .925           |
| Health Coaching | 90 (75)    | +0.09 (8.5) |            | +1.8 (9.7)     |               |
| Health + Activation Coaching | 89 (78) | +0.55 (6.6) |            | +2.7 (5.8)     |               |

Significant P values are shown in bold.

**Limitations and Strengths**

In this pilot RCT we did not record the number of patients who declined to be screened, nor did we measure ethnicity or tumor histological subtype. Follow-up duration was relatively short meaning that sustainability of the interventions is not known. Analyses were not powered or intended to test efficacy but to the extent that quantitative data can be weighed, outcome scales conflicted on whether improvements were seen in both intervention arms or sustained until the study endpoint; reasons for these conflicts are not clear and will require more data to unpick. Whether the interventions can be scaled beyond the study authors also
remains open: it will benefit future studies to manuallize each separate coaching session. The optimal timing for coaching, and mechanisms of action, if any, are not known and likewise questions for future studies. Therefore apart from the primary outcome of feasibility, much of the current output is preliminary.

In conducting the study, we became aware that “coaching” itself remained poorly defined. We established that it is feasible for fatigued patients to engage with people who call themselves coaches but did not examine which elements distinguish a coaching intervention from a more typical clinical intervention. What aspects of coaching are irreducible? What makes a good coach? Who is best placed to coach cancer patients in healthcare settings? Others may know the answers to these questions, but we do not. Exploring them may be helpful for future studies.

Alongside these limitations BT-LIFE had several novel or notable features. To our knowledge it is the first study to establish the feasibility of targeting highly fatigued brain tumor patients with complex interpersonal interventions. It is one of a handful of trials to report a signal of clinical and statistical effect on fatigue in these patients. The study blended private, charity, and health sectors to present a successful model of “multi-sectoral research”. Multisectoral research partnerships in which each sector has something valuable to the others have great potential for synergy, innovation, and new ways of delivering new interventions that may benefit patients.

Results in Context

In neuro-oncology, there is mounting evidence from RCTs that psychostimulant medication is ineffective for fatigue and most secondary QOL outcomes, while two pilot RCTs of non-pharmacological interventions have reported preliminary improvements in fatigue and neurocognitive functioning. Although the effectiveness of any non-pharmacological strategy is yet to be proven for brain tumor patients, the wider oncology literature supports a shift in this direction: exercise, resistance training, core stability, psychological therapies, yoga, mindfulness, and hypnosis are listed among the therapies showing varying degrees of promise for fatigue in other cancer populations.

Engagement with HC overall was good. Every patient who started AC continued to the second session. Most patients who were interviewed reported benefits on symptoms, lifestyle behaviors, or ability to manage ongoing fatigue. These insights suggest that fatigue is not an intractable or treatment-refractory problem: it may simply be that such a complex symptom is better suited to management by complex interventions.

Next Steps

The next steps will study the essence, scalability, and efficacy of the coaching interventions piloted in BT-LIFE. A Phase II trial could formally manuallize interventions, develop mechanisms to ensure blinding of outcome assessors, and perhaps stratify by symptom severity.

Conclusion

BT-LIFE established that lifestyle coaching interventions are feasible to deliver to fatigued brain tumor patients. Coaching interventions were manageable, acceptable, and safe, with preliminary evidence of benefit on fatigue and mental health outcomes. Further trials are justified to test the efficacy of lifestyle coaching interventions in this highly impaired patient group.

Supplementary material

Supplementary material is available online at Neuro-Oncology (http://neuro-oncology.oxfordjournals.org/).

Acknowledgements

MW is supported by the Imperial Biomedical Research Centre. We gratefully acknowledge the independent Trial Steering Committee members (Prof. Dr. Martin Klein, Prof. Anthony Byrne, Dr. Karin Gehring, and Ms. Nicola Greenlaw). We also gratefully acknowledge Mr. Paul Brennan, Kenny Scott, Jamie McCubbin, Leigh Baxter, Dorothy Air, Val Renton, Elaine O’Neill, Diane Catterall, Margaret Maxwell, Prof. Jon Stone, and Prof. Alan Carson for their help facilitating or commenting on the study. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Funding

BT-LIFE was funded by The Brain Tumour Charity (grant number G000436). Post-hoc follow-up analyses (LEMH, AC) were funded by Public Health Scotland, the Edinburgh Centre for Neuro-Oncology Endowment Fund, the Beatson West of Scotland Cancer Centre, and the Christie NHS Foundation Trust.

Conflict of Interest

GA is a private personal trainer. Out-with the study he created the specific HC model utilized here and uses it in private practice. Within the study he was contracted to give HC to participants at the Edinburgh and Glasgow sites. HB and CC are employees of the UK brain tumor charity brainstrust which offers life coaching to brain tumor patients and their careers out-with the study. Within the study brainstrust was contracted to give AC to participants on all three sites. None of these individuals had any role in the collection, analysis, or interpretation of any data presented in this manuscript. All other authors report no conflict of interest.
Authorship

Experimental design: AGR, WH, SR, CT, GA, HB, RH, JD, DG, CH, MW, CM, AJC, RG. Implementation: AGR, WH, AW, MM, LW, SR, CT, GA, HB, JD, MW, AG, JE, CC, EM, MW, CM, AJC, RG. Analysis/interpretation of data: AGR, CT, LEMH, AC, RH, JC, MW, CM, AJC, RG. Writing manuscript: all authors. Final approval: all authors.

References

1. van Coevorden-van Loon EMP, Coomans MB, Heijenbrok-Kal MH, Ribbers GM, van den Bent MJ. Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. J Neurooncol. 2017;133(2):237–246.

2. Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Neurosurg. 2007;99(1):61–67.

3. Schei S, Solheim O, Jakola AS, Sagberg LM. Perioperative fatigue in patients with diffuse glioma. J Neurooncol. 2020;147(1):97–107.

4. Nassiri F, Price B, Shehab A; International Consortium on Meningiomas, et al. Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro Oncol. 2019;21(Suppl 1):32–43.

5. IJzerman-Korevaar M, Snijders TJ, de Graeff A, Teunissen SCCM, de Vos FF. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. J Neurooncol. 2018;140(3):485–496.

6. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang D-H. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707–2715.

7. Coomans MB, Dirven L, Aaronson NK, et al. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? Neuro Oncol. 2019;21(11):1447–1457.

8. The Brain Tumour Charity. Losing Myself: The Reality of Life With a Brain Tumour. Farnborough: The Brain Tumour Charity, 2015.

9. James Lind Alliance Priority Setting Partnership. Neuro-Oncology Top 10. Southampton: James Lind Alliance; 2015.

10. Day J, Yust-Katz S, Cachia D, et al. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev. 2022;9(9):CD001137.

11. Butler JM, Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled randomized clinical trial of o-threo-methylphenidate HCI in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–1501.

12. Page BR, Shaw EG, Lu L, et al. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol. 2015;17(10):1393–1401.

13. Lee EQ, Muzikansky A, Drappatz J, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016;18(6):849–854.

14. Boele FW, Douw L, de Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013;15(10):1420–1428.

15. Laigle-Donadey F, Ducray F, Boone M, et al. A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: an ANOCEF trial [DXA]. Neurooncol Adv. 2019;1(1):vdx043.

16. Porter AB, Liu H, Kohli S, et al. Efficacy of treatment with armodafinil for cancer-related fatigue in patients with high-grade glioma: a phase 3 randomized clinical trial. JAMA Oncol. 2022;8(2):259–267.

17. Lovell MR, Lueck T, Boyle FM, et al. Patient education, coaching, and self-management for cancer pain. J Clin Oncol. 2014;32(16):1712–1720.

18. Coolbrandt A, Wildiers H, Aertgeerts B, et al. Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: a systematic review of randomized controlled trials. Int J Nurs Stud. 2014;51(3):495–510.

19. Duncan M, Moschopoulou E, Herrington E, et al. Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors. BMJ Open. 2017;7(11):e015860.

20. Kenyon M, Young F, Mufti GJ, et al. Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability. Eur J Cancer Care (Engl). 2015;24(4):531–541.

21. Hawkes AL, Chambers SK, Pakenham KI, et al. Effects of a telephonedelivered multiple health behavior change intervention (CanChange) on health and behavioral outcomes in survivors of colorectal cancer: a randomized controlled trial. J Clin Oncol. 2013;31(18):2313–2321.

22. Ye ZJ, Qiu HZ, Liang MZ, et al. Effect of a mentor-based, supportive-expressive program, be resilient to breast cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial. Br J Cancer. 2017;117(10):1486–1494.

23. Gehring K, Stuiver MM, Visser E, et al. A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma: a proof of concept. Neuro Oncol. 2020;22(1):103–115.

24. Yun HY, Kim YA, Lee MK, et al. A randomized controlled trial of physical activity, dietary habit, and distress management with the Leadership and Coaching for Health (LEACH) program for disease-free cancer survivors. BMC Cancer. 2017;17(1):298.

25. Wu C, Zheng Y, Duan Y, et al. Nonpharmacological interventions for cancer-related fatigue: a systematic review and bayesian network meta-analysis. Worldviews Evid Based Nurs. 2019;16(2):102–110.

26. Milbury K, Li J, Weathers SP, et al. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. Neuro Oncol Pract. 2019;6(4):311–320.

27. Mendoza TR, Wang XS, Cleland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186–1196.

28. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–1026.

29. Dilts RB. Changing Belief Systems with NLP. Scotts Valley, CA: Dilts Strategy Group; 2018.

30. Miller WR, Sanchez VC. Motivating young adults for treatment and lifestyle change. In: GL Howard, ed. Issues in Alcohol Use and Misuse by Young Adults. Notre Dame: University of Notre Dame Press; 1993:55–82.

31. Whitmore J. Coaching for Performance. 5th ed. Boston, MA: Nicholas Brealey Publishing; 2017.

32. Coens C, Pe M, Dueck AC, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol. 2020;21(2):e83–e96.

33. Brown FD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol. 2020;38(10):1019–1029.
34. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.

35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.

36. Ashworth M, Robinson SI, Godfrey E, et al. Measuring mental health outcomes in primary care: the psychometric properties of a new patient-generated outcome measure, PSYCHLOPS (Psychological Outcome Profiles). Prim Care Mental Health. 2005;3(4):261–270.

37. EuroQol Research Foundation. EQ-5D-5L User Guide. 2019 Available at: https://euroqol.org/publications/user-guides. Accessed July 27, 2021.

38. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord. 2013;36(3–4):242–250.

39. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, eds. Analysing Qualitative Data. London: Routledge; 1994.

40. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117. https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-13-117

41. Pawson R and Tilley N. Realistic Evaluation. London: Sage; 1997.

42. Medical Research Council. Developing and Evaluating Complex Interventions: New Guidance. London: Medical Research Council; 2006.

43. Grégoire C, Faymonville ME, Jerusalem G, Gossieres O, Vanhaudenhuyse A. Psycho-oncology interventions focusing on fatigue and sleep disturbances. Curr Opin Oncol. 2022;34(4):270–278.